

CORRECTION

Open Access



Correction to: Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation

Yaru Huang^{1†}, Xiaotong Sun^{1†}, Zhaodong Juan^{1*}, Rui Zhang¹, Ruoguo Wang², Shuqi Meng¹, Jijia Zhou¹, Yan Li¹, Keyou Xu¹ and Keliang Xie^{1*}

Correction to: BMC Anesthesiol 21, 104 (2021)
<https://doi.org/10.1186/s12871-021-01334-5>

In the article “Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation. *BMC ANESTHESIOLOGICAL* 2021, 21(1):104” [1] 1uM MCC950 is corrected to 1 μM MCC950 in the Fig. 1a on page 3 of 12.

Author details

¹Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, School of Anesthesiology, Weifang Medical University, No. 7166, Baotong West Street, Weicheng District, Weifang 261021, China. ²Department of Pain, Affiliated Hospital of Weifang Medical University, Weifang 261000, China.

Published online: 10 May 2021

Reference

1. Huang Y, Sun X, Juan Z, Zhang R, Wang R, Meng S, et al. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation. *BMC Anesthesiol.* 2021;21:104. <https://doi.org/10.1186/s12871-021-01334-5>.

The original article can be found online at <https://doi.org/10.1186/s12871-021-01334-5>.

* Correspondence: juanzd@wfmw.edu.cn; xiekeliang2009@hotmail.com

[†]Yaru Huang and Xiaotong Sun contributed equally to this work.

¹Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, School of Anesthesiology, Weifang Medical University, No. 7166, Baotong West Street, Weicheng District, Weifang 261021, China
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 1 Experimental protocol and four time points for detecting the beating rate of cardiomyocytes (CMs). **a** Experimental protocols. Cardiac fibroblasts (CFs), cardiomyocytes (CMs) and cocultured CMs and CFs (CMs + CFs) were randomly assigned to one of five groups: 1) C group, in which the cells were incubated under normal conditions in a CO₂ incubator; 2) M group, in which the cells were exposed to hypoxia/reoxygenation as we described above; 3) D group, in which the cells were pretreated with 1 μg/ml dexmedetomidine (DEX) 2 h before hypoxia/reoxygenation; 4) 950 group, in which the cells were treated with 1 μM MCC950 during hypoxia/reoxygenation and 2 h before it; and 5) D + 950 group, in which the cells were treated with 1 μM MCC950 during DEX preconditioning and hypoxia/reoxygenation., **b** Four time points for detecting the myocardial cell beat frequency of cocultured CMs and CFs (CMs + CFs). We detected the beat frequency of CMs at these four time points as indicated by the arrow. 1–2 (group M): 1, normal; 2, after hypoxia/reoxygenation. 3–4 (group D): 3, normal; 4, after hypoxia/reoxygenation. DEX, dexmedetomidine; CMs, cardiomyocytes; CFs, cardiac fibroblasts; CMs + CFs, cocultured cardiomyocytes and cardiac fibroblasts; MCC950, a potent selective NLRP3 inhibitor